bs-0031R [Primary Antibody]
BTG2 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: BTG2

Immunogen Range: 31-110/158


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 7832

Swiss Prot: P78543

Source: KLH conjugated synthetic peptide derived from human BTG2

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

BTG2 is a member of the BTG/Tob family. This family has structurally related proteins that appear to have antiproliferative properties. BTG2 is involved in the regulation of the G1/S transition of the cell cycle. It modulates transcription regulation mediated by ESR1(referenced from Entrez Gene). BTG2 expression is induced in vivo during neurogenesis, and the gene is transiently expressed in vitro in rat pheochromocytoma PC12 cells after induction of neuronal differentiation by addition of nerve growth factor (NGF); suggesting that BTG2 is functionally significant during the neuronal differentiation process (PMID: 12360398).

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 17


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Pig
Rabbit
Guinea Pig

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Qu D et al. ATF3 mRNA, but not BTG2, as a possible marker for vital reaction of skin contusion. Forensic Sci Int. 2019 Sep 12;303:109937. Read more>>
  • Liu Jinpeng. et al. miR-92b-3p protects retinal tissues against DNA damage and apoptosis by targeting BTG2 in experimental myopia. J TRANSL MED. 2024 Dec;22(1):1-15Read more>>
  • Pan Binhui. et al. Deciphering the molecular nexus of BTG2 in periodontitis and diabetic kidney disease. BMC MED GENOMICS. 2024 Dec;17(1):1-14Read more>>
VALIDATION IMAGES

Lane 1: HepG2 lysates; Lane 2: Hcclm3 lysates probed with BTG2 Polyclonal Antibody, Unconjugated (bs-0031R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.


Lane 1: Human K562 cell lysates; Lane 2: Human 293T cell lysates; Lane 3: Human HepG2 cell lysates probed with BTG2 Polyclonal Antibody, Unconjugated (bs-0031R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.